• GABRA1 Frameshift Variants Disrupt GABAAR Proteostasis

  2026-09-18

  The reference preprint shows that four clinical GABRA1 frameshift variants impair α1-subunit trafficking, channel function, and endoplasmic-reticulum proteostasis, but do so with variant-specific severity. Its main contribution is to connect the precise transmembrane losses caused by each truncation with overlapping yet distinct quality-control responses, providing a mechanistic framework for interpreting GABAAR-associated epilepsy variants.

• TCAIM, OGDH, and Mitochondrial Metabolic Control

  2026-09-18

  A 2025 Molecular Cell study identifies TCAIM as a mitochondrial DNAJC co-chaperone that specifically binds native OGDH and promotes its reduction through HSPA9 and LONP1. The work reveals that mitochondrial proteostasis can regulate a rate-limiting TCA-cycle enzyme, thereby changing OGDH complex activity and carbohydrate metabolism in cells and mice.

• Sulfo-NHS-Biotin for Single-Cell Assays

  2026-09-17

  Sulfo-NHS-Biotin enables aqueous, amine-selective labeling for cell-surface profiling, affinity capture, and functional single-cell assays. This guide translates the nanovial-based screening strategy from a UCLA dissertation into practical labeling, optimization, and troubleshooting decisions.

• FPH1 (BRD-6125) Hepatocyte Workflow Guide

  2026-09-17

  FPH1 (BRD-6125) connects hepatocyte expansion with functional endpoints such as albumin, CYP3A4, AFP, nuclei count, and mitotic activity. This practical guide shows how to deploy it in primary human hepatocyte culture and induced pluripotent stem cell hepatocyte differentiation while separating validated product parameters from assay-development recommendations.

• Sulfo-NHS-SS-Biotin for Surface Protein Workflows

  2026-09-16

  Sulfo-NHS-SS-Biotin enables aqueous, amine-directed labeling of intact-cell surfaces and purified proteins, with a disulfide spacer that supports reducing-agent release. This guide translates transporter-trafficking findings in TGEV-infected intestinal cells into practical surface-versus-total protein assays, affinity purification workflows, and troubleshooting decisions.

• Go 6983: PKC Logic in Striatal Circuit Assays

  2026-09-16

  Go 6983, a pan-PKC inhibitor, can help test how excessive PKC activity links Neuroligin 1 loss to striatal D2-MSN excitability and repetitive behavior. This article translates the reference study into a rigorous, cell-type-aware assay strategy while clarifying pharmacological limitations and cross-domain applications.

• DCFH-DA Workflow for Intracellular ROS Detection

  2026-09-15

  Build more informative oxidative-stress experiments with DCFH-DA across microscopy, flow cytometry, and plate-based formats. The workflow pairs rapid ROS readouts with orthogonal DNA-break profiling to distinguish redox changes from downstream genome damage.

• WAY-100635: A 5-HT1A Assay Framework

  2026-09-15

  WAY-100635 enables selective interrogation of 5-HT1A signaling across binding, functional, behavioral, and imaging studies. This article presents an assay-centered framework linking serotonin receptor antagonist research with emerging pain-affect models while clarifying interpretation, controls, and handling.

• Sulfo-NHS-SS-Biotin for Cleavable Surface Proteomics

  2026-09-14

  Sulfo-NHS-SS-Biotin combines surface-restricted amine labeling with a reducible disulfide spacer, making it useful for tracking membrane trafficking and reversible affinity capture. This workflow translates lysosomal damage biology into experimentally testable measurements of protein accessibility, purification, and label removal.

• 4-Ethylphenyl Sulfate: An Assay Design Guide

  2026-09-14

  4-Ethylphenyl sulfate is a microbiota-derived metabolite relevant to renal dysfunction biomarker and gut microbiota-brain interaction research. This guide focuses on assay design, surface adsorption, matrix effects, and evidence boundaries for translational studies.

• Valemetostat (DS-3201) and Dual EZH1/2 in ATL

  2026-09-13

  The reference paper describes why simultaneous EZH1 and EZH2 inhibition is a rational epigenetic strategy for adult T-cell leukemia/lymphoma (ATL), where persistent H3K27me3-mediated repression contributes to disease biology. It also summarizes phase 2 evidence supporting Valemetostat in relapsed or refractory ATL while highlighting the need for larger, comparative, and biomarker-informed studies.

• BIIE 0246: Reliable Y2R Assay Workflows

  2026-09-12

  Learn how BIIE 0246 (SKU B6836) can strengthen mechanistic studies involving neuropeptide Y Y2 receptor signaling, cell-based assays, and pathway-specific controls. This scenario-driven guide covers design, dosing, interpretation, storage, and vendor-selection considerations without overstating what the compound can establish.

• 25-Hydroxycholesterol Reprograms Tumor Macrophages

  2026-09-11

  Xiao et al. identify CH25H and lysosomal 25-hydroxycholesterol as an immunometabolic checkpoint that activates AMPKα and reinforces STAT6-dependent ARG1 production in tumor-associated macrophages. The study connects cholesterol handling to macrophage suppression, CD8+ T-cell surveillance, and improved anti-PD-1 responses, providing a mechanistic framework for converting cold tumors into more inflamed tumors.

• EZ Cap™ Firefly Luciferase mRNA for Delivery

  2026-09-11

  EZ Cap™ Firefly Luciferase mRNA provides a Cap 1 and poly(A)-optimized reporter for separating nanoparticle distribution from productive cytosolic expression. This article translates recent lymph-node imaging findings into practical assay-design decisions for mRNA delivery, translation, and in vivo bioluminescence imaging.

• MMP-Responsive Hydrogel Delivery in Fibrous Dysplasia

  2026-09-10

  This reference study introduces an injectable hyaluronic acid hydrogel containing triglycerol monostearate nanoparticles for matrix metalloproteinase-responsive, sustained delivery of the RANKL inhibitor AS2676293. In a GNASR201C knock-in mouse model, perilesional treatment reduced fibrous dysplasia progression and improved bone microarchitecture, supporting lesion-responsive delivery as a potential way to limit systemic exposure.

8441 records 1/563 page Next 12345 下5页 Last page